Your browser doesn't support javascript.
loading
Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas.
Hu, Bei; Korsos, Victoria; Palomba, M Lia.
Affiliation
  • Hu B; Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute/Wake Forest School of Medicine, Charlotte, NC, United States.
  • Korsos V; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Palomba ML; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Front Oncol ; 14: 1394057, 2024.
Article in En | MEDLINE | ID: mdl-39011476
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: United States Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: United States Country of publication: Switzerland